ADGRG6 and urinary bladder carcinoma: These results indicate that the mutation in ADGRG6 enhancer changes its regulatory activity and acts like a novel oncogenic driver critical for pathological angiogenesis in UBC, providing a potential target for bladder cancer diagnostic screening and treatment.